Epidemiologist Erin Bowles, MPH, is looking at cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Health Care Systems Cancer Research Network (CRN) — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of care in cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20 years has provided her with expertise in data collection and quality control for many subject areas. She is also a manager of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to junior faculty.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Delate T, Witt DM, Ritzwoller D, Weeks JC, Kushi L, Hornbrook MC, Aiello Bowles EJ, Schrag D. Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer. Oncologist. 2012;17(3):419-27. doi: 10.1634/theoncologist.2011-0323. Epub 2012 Feb 14. PubMed
Trentham-Dietz A, Sprague BL, Wang J, Hampton JM, Buist DS, Aiello Bowles E, Sisney G, Burnside E, Hemming J, Hedman C. Phenol xenoestrogens and mammographic breast density. Cancer Epidemiol Biomarkers Prev. 2012;21(3):561-2. Epub 2012 Feb 15. PubMed
Aiello Bowles EJ, Buist DS, Chubak J, Yu O, Johnson J, Chestnut J, Boudreau DM. Endocrine therapy initiation from 2001 through 2008 varies by age of breast cancer diagnosis and tumor size. J Oncol Pract. 2012;8(2):113-20. PubMed
Buist DS, Walker R, Aiello Bowles EJ, Carney PA, Taplin SH, Onega T, Kerlikowske K, Clinton W, Miglioretti DL. Screening mammography use among current, former, and never hormone therapy users may not explain recent declines in breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):720-7. doi: 10.1158/1055-9965.EPI-11-1115. Epub 2012 Feb 1. PubMed
McCahill LE, Single R, Aiello Bowles EJ, Feigelson HS, James TA, Barney T, Engel JM, Onitilo AA. Variability in the practice of re-excision following initial breast conservation for invasive breast cancer. JAMA. 2012 Feb 1;307(5):467-75. PubMed
Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, Bowles EJ, Stanczyk FZ, Sisney GS, Skinner HG. The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Res Treat. 2012 Jan;131(1):255-65. Epub 2011 Aug 17. PubMed
The division contributes to research across the institute with methodological and subject matter expertise.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease.
Study suggests disparities at screening sites may influence lag in follow-ups.